{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI was not estimable due to fewer number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI was not estimable due to fewer number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI was not estimable due to fewer number of participants with events.","groupId":"OG002","lowerLimit":"30.42","upperLimit":"NA","value":"35.023"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"65"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).","id":"OG000","title":"Randomized Phase: Brigatinib 90 mg QD/180 QD"},{"description":"Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).","id":"OG001","title":"Randomized Phase: Crizotinib 250 mg BID"},{"description":"Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).","id":"OG002","title":"Crossover Phase: Brigatinib 90 mg QD/180 mg QD"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (Up to 56 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}